Global Neurological Biomarkers Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
“Global Neurological Biomarkers Market” is an upcoming market research report by MarketResearch.biz. Critical data and information on the neurological biomarkers market, such as revenue details, competitive landscape, market trends, restraints, drivers, details of key players, growth opportunities, and recent developments, are included. Presentation of both historical and projected revenue details in the report provides an in-depth understanding of the potential in the market currently and over the next 10 years. The report includes detailed and insightful profiles of the top players in the global neurological biomarkers market. In addition, extensive primary and secondary research efforts are conducted to ensure the accuracy of the research findings and conclusions. Also, findings and conclusions of the research report are verified by industry experts before being included in the report. The global neurological biomarkers research report is segmented on the basis of application, type, end-use, and regions and countries.
Biomarkers, the biological markers, are used to measure biological states. It is generally used for indicating pathogenic and normal biological processes to a therapeutic intervention. This is also used in combination for accessing an individual’s disease condition. Scientists are focusing on exploring more on both functional and structural differences of neurological differences. The most common form of dementia is Alzheimer’s, which is affecting more than 12 million people around the world. Neuropsychological and neuroimaging probes can predict Alzheimer's prior to behavioral tests diagnose. Thus, pre-assessment tests such as functional magnetic resonance imaging (fMRI) and Positron emission tomography (PET) and are fueling demand for neurological biomarkers.
Among some of the major factors driving growth of the global market are increasing prevalence of various neurological diseases and growing emphasis on early diagnosis and treatment. According to World Health Organization (WHO), more than 300 million people of all ages suffer from clinical depression around the world. Lack of efficient diagnosis in both developed and developing countries enhance the mortality rate of patience with neurological disorders. Neuro-disorders that can affect the spine, brain, or nerves are more than 600. Some of the prevalent disorders among them are Alzheimer’s disease, brain tumors, cerebral stroke, epilepsy, and Parkinson’s disease. Most of the neurological disorders are rare and complicated, which require further investigation to understand the underlying pathophysiology. Other factors expected to drive growth of the global neurological biomarkers market are rising funding for neurological diagnostics and proactive governmental initiatives. Initiatives by government organizations such as National Institute of Neurological Disorders and Stroke (NINDS) to enforce regulatory strategies and to evaluate diagnostic and therapeutic approaches are expected to create growth opportunities for key players in the global neurological biomarkers over the forecast period.
Global Neurological Biomarkers Market Segment Analysis:
By Application: The Alzheimer’s disease segment continues to account for highest revenue share in the global neurological biomarkers market among other application segments. This can be attributed to its high prevalence among old people and sexagenarians.
By Type: The genomic segment among the type segments is expected to continue its dominance in terms of revenue share over the forecast period. This can be attributed to technological advancements and increasing awareness among consumers. Also, changing diagnostic paradigm towards genetic counseling and gene analysis is attributed to growth of this segment in the global market.
Global Neurological Biomarkers Market Regional Analysis:
North America accounts for highest revenue share currently and this dominance of the region is expected to continue over the forecast period. This can be attributed to strong commercial performances of neurological diagnostics in the U.S. Others factors attributed to this growth are proactive government initiatives, local presence of key manufacturers, and increase in healthcare expenditure in the region.
Global Neurological Biomarkers Market Segmentation:
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
- Hospital Laboratories
- Independent Clinical Diagnostic Centers
- Research Organizations
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- Myriad RBM
- Thermo Fisher Scientific Inc.
- Athena Diagnostics
- Bio-Rad Laboratories, Inc.
- AbaStar MDx, Inc.
- Acumen Pharmaceuticals
- BANYAN BIOMARKERS, INC.
- Alseres Pharmaceuticals, Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!